What Amycretin is
Amycretin is Novo Nordisk’s attempt to hit the same two targets as its CagriSema combination — GLP-1 and amylin — but with a single molecule instead of two drugs, and in both an oral pill and an injectable form. It is one of the earliest-stage molecules in the obesity pipeline, and it is not approved or available anywhere.
Mechanically, Amycretin is a single-molecule (unimolecular) GLP-1 and amylin receptor agonist, in development as both a once-daily oral pill and a once-weekly injection.
What the trials show
The most eye-catching figure is a 24.3% average weight loss at 36 weeks with the 60 mg subcutaneous dose in a Phase 1b/2a study (published in The Lancet, July 2025) — but that was a small, single-site trial with a notable dropout rate, so it should be read as an early signal, not a confirmed result. A Phase 2 diabetes study reported up to about 14.5% (injectable) and 10.1% (oral) at 36 weeks.
Can you get Amycretin yet?
Amycretin is not available and will not be for years. It is at the Phase 1b/2a to Phase 2 stage, with Phase 3 only expected to begin in 2026 and no regulatory filing anywhere. Analysts do not expect a possible market entry before roughly 2028–2029, and those are estimates. Any "amycretin" sold to consumers now is not a legitimate approved product.
Keep the stage in view: the 24.3% figure comes from the earliest kind of human trial (Phase 1b/2a), small and single-site, and is the full-adherence number. It is promising but unconfirmed — do not read it as settled Phase 3 efficacy, and do not confuse amycretin with the separate CagriSema combination even though their targets overlap.
The options you can actually get now
While Amycretin moves through trials, the FDA-approved GLP-1 medicines are available today. If weight loss is the goal, see our comparison of the best approved GLP-1 options, the semaglutide and tirzepatide hubs, and the full list of GLP-1 medications.